HELPS Study - A Study of Peginterferon Alfa-2a (Pegasys) in Patients With Chronic Hepatitis C (CHC) and End-Stage Renal Disease (ESRD)

Inclusion Criteria: * Serum hepatitis C virus ribonucleic acid (HCV RNA) quantifiable at greater than (\>) 600 IU/mL * Liver biopsy consistent with chronic hepatitis C infection obtained within 2 years of enrollment * Compensated liver disease without cirrhosis * Participants with end-stage renal disease undergoing hemodialysis * Negative serum pregnancy test (for women of childbearing potential) documented within the 24-hour period prior to the first dose of study drug * All fertile participants must have been using effective contraception during treatment with study drug Exclusion Criteria: * Interferon therapy at any previous time * Liver cirrhosis * Signs and symptoms of hepatocellular carcinoma * History or other evidence of decompensated liver disease * Any investigational drug less than or equal to 6 weeks prior to the first dose of study drug * History or other evidence of a medical condition associated with chronic liver disease other than HCV (e.g., hemochromatosis, autoimmune hepatitis, metabolic liver disease, alcoholic liver disease, toxin exposures) * Poorly controlled diabetes * Thyroid dysfunction not adequately controlled * Evidence of severe retinopathy or clinically relevant ophthalmological disorder * Severe hyperparathyroidism defined as intact Parathyroid Hormone (PTH) \> 800 picogram/milliliter (pg/mL) * Therapy with any systemic anti-viral, anti-neoplastic or immunomodulatory treatment ≤ 6 months prior to the first dose of study drug * Acute renal failure * Women with ongoing pregnancy or breast feeding * Positive test at screening for anti-HAV IgM Ab (hepatitis A virus immunoglobulin M antibody), hepatitis B surface antigen (HBsAg), anti-HBc (hepatitis B core) IgM Ab, anti-HIV (human immunodeficiency virus) Ab